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Mounting evidence has shown that the risk of metabolic syndrome (MetS) is substantially
overlapping in the diagnostic subgroups of psychiatric disorders. While it is widely
acknowledged that patients receiving antipsychotic medications are at higher risk
of MetS than antipsychotic-naive ones, the association between antidepressants
and MetS is still debated. The goal of our mini review was to analyse the
relationship among depressive symptoms, antidepressant use and the occurrence of
MetS. Adhering to PRISMA guidelines, we searched MEDLINE, reference lists and
journals, using the following search string: (((“Mental Disorders”[Mesh]) AND “Metabolic
Syndrome”[Mesh]) AND “Antidepressive Agents”[Mesh]), and retrieved 36 records. Two
reviewers independently assessed records and the mini review eventually included the
data extracted from 8 studies. The Newcastle-Ottawa Scale was used to assess the
quality of the selected studies. Overall, the results of the mini review seem to support the
association among depressive symptoms, antidepressants therapy andMetS. Except for
H1-R high-affinity ones, the relationship between antidepressants and MetS still needs
to be clarified. Considering the widespread prescription of antidepressants, both on
behalf of psychiatrists and primary care physicians, further research on this topic is
recommended.
Keywords: metabolic syndrome, depression, antidepressants, cardiometabolic disease, review, preferred
reporting items for systematic reviews and meta-analyses (PRISMA) statement
INTRODUCTION
Metabolic syndrome (MetS) is a cluster of obesity, insulin resistance, hypertension, impaired
glucose tolerance or diabetes, hyperinsulinemia, elevated triglycerides and low high-density
lipoprotein (HDL) concentrations (1, 2). A syndrome can be regarded as “a clustering of factors
that occur together more often than by chance alone and for which the cause is often uncertain”
(3). According to the International Diabetes Federation (IDF) definition, MetS is characterized by
central adiposity plus two or more of the following four factors (4): (1) raised concentration of
triglycerides:≥150 mg/dl (1.7 mmol/l) or specific treatment for this lipid abnormality; (2) reduced
concentration of HDL cholesterol: 40 mg/dl (1.03 mmol/l) in men and 50 mg/dl (1.29 mmol/l)
in women, or specific treatment for this lipid abnormality; (3) raised blood pressure: systolic blood
pressure≥130 mmHg or diastolic blood pressure≥85 mmHg or treatment of previously diagnosed
hypertension; and (4) raised fasting plasma glucose concentration ≥100 mg/dl (5.6 mmol/l) or
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previously diagnosed type 2 diabetes. Furthermore, the IDF
lists ethnic group–specific thresholds for waist circumference to
define central adiposity (5).
National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) criteria require three out of five
factors to establish the diagnosis of MetS, i.e., abdominal
obesity (waist circumference >88 cm for women or > 102 cm
for men), increased triglycerides (≥150 mg/dL), reduced HDL
cholesterol (<50 mg/dL for women or <40 mg/dl for men), high
blood pressure (≥130/85) (6) and high fasting glucose (≥100
mg/dL) (7).
A vast body of literature (8–16) has pointed to a major role
of mental illness (especially bipolar disorder, depression, anxiety,
and suicidal ideation) in the future development of MetS and
associated diseases. A variety of factors may be responsible for
MetS in patients suffering from mental illnesses, such as lifestyle,
diet, tendency to insulin resistance, and medication side-effects,
especially those of antipsychotics (17). Antipsychotics, mostly
second generation ones (SGAs) such as clozapine, olanzapine,
and risperidone, seem to be involved in the development of MetS
(18, 19). Albeit the pathophysiology of SGAs-induced metabolic
alterations is not yet fully elucidated, increased food intake,
weight gain, hyperglycemia, lipid accumulation in adipose cells
and liver are hallmarks of this problem (19).
Several studies (20–23) have shown a high comorbidity
between major depressive disorder (MDD) and MetS (24, 25).
Depression can cause a 2-fold increase in the risk of MetS
in the general population, probably due to poor health-related
behaviors (26). Furthermore, independent of the psychiatric
disorder diagnosis, antidepressants may have a direct impact on
MetS (27), and overall negative consequences for cardiometabolic
health (28–31).
While prescription of antidepressant medication is
increasing (30) and there is evidence of weight gain induced
by antidepressants (31), the association between Mets and
antidepressants still remains only partially understood. The
introduction of tricyclic antidepressants (TCAs) in the late
1960s, followed by that of selective serotonin re-uptake
inhibitors (SSRIs) in the 1980s, together with the increase of
long-term prescriptions (in the 1990s and 2000s) and to the more
recent use of higher doses of antidepressants, have contributed
to a tendency toward over prescribing of antidepressants (32).
Although there is much evidence supporting the association
between MetS dysregulations and the use of TCAs, particularly
abdominal obesity (33, 34), the effects of SSRIs on MetS are far
less clear (35, 36).
Considering the possible role of mental illness in the future
development of MetS and the need to clarify the impact of
antidepressant treatment on MetS, the aim of this mini-review
was to address the relationship among depressive symptoms,
antidepressant use and the occurrence of MetS.
METHODS
Adhering to PRISMA guidelines, a literature search was
conducted in MEDLINE on 13 February 2018, using the
following search string: (((“Mental Disorders”[Mesh])
AND “Metabolic Syndrome”[Mesh]) AND “Antidepressive
Agents”[Mesh]). The search was restricted to the English
language. To be included in the mini review, papers had to be
cross-sectional or cohort studies designed with the purpose of
analyzing the association between MetS, depressive symptoms
or antidepressants therapy. Two reviewers (CG and EG)
independently triaged the titles and then the abstracts to exclude
those that were clearly inappropriate. Possible disagreement
between reviewers was resolved by joint discussion with a third
review author (PZ). Reasons for the exclusion of papers from the
review were reported in the PRISMA flow diagram.
After selection of the relevant studies, reviewers extracted and
tabulated data using a standard form (Table 1). Extracted data
included country of origin, research objectives, databases and
period assessed, study design, participants’ features. Some data
were tabulated, while other, including those about educational
and occupational level, socio-demographic data collection
methods, lifestyle data collection methods, anthropometric
measurements (including waist circumference and Body Mass
Index [BMI]), were reported in the text description in the Results
section.
Outcome data were presented as count data. Narrative data
extracted from the papers included in this mini review are
reported inTable 1. Where necessary, text descriptions were used
to highlight information that was not captured in the Table.
Finally, the Newcastle-Ottawa Scale (NOS) (44) was used to
assess the quality of the selected cohort studies. The quality of
cross sectional studies was evaluated through an adapted version
of the NOS (45).
The need for an Ethics Committee approval was waived, since
we just collected and synthesized data from previous clinical trials
in which informed consent had already been obtained.
RESULTS
Selection
The PubMed literature search identified 36 articles. After title,
abstract, and eventually full-text screening, 8 papers (1, 37–43)
met inclusion criteria for this mini-review (see Figure 1 for more
details) (46).
Study Design and Features
Of the 8 studies included in our mini-review, 2 used a prospective
cohort design (37, 41), and 6 a cross-sectional design (1, 38–
40, 42, 43). In 3 studies the number of participants was ≤99
(38, 40, 43), 2 studies had a sample ranging from 100 to 240
individuals (37, 41), 3 studies included more than 250 patients
(1, 39, 42). The average number of participants was of 277 ±
296 (SD) (min 60, max 970 participants). Only one study (39)
was multicentric, involving 5 centers, while the other 7 ones were
monocentric. Six studies were performed in Europe (38–43), 1 in
the United States of America (1), and 1 in Asia (37). Only five
studies reported data on the recruitment setting: specifically, two
studies included inpatients from a psychiatric ward (40, 41); two
studies recruited outpatients (1, 37), while the sample was mixed
(both inpatients and outpatients) in 1 study (39). Three studies
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FIGURE 1 | PRISMA 2009 flow diagram. Adapted from Moher et al. (47).
did not report information about recruitment setting (38, 42, 43).
Only 2 studies (38, 41) reported data about the staff involved in
the research, composed by doctors and nurses.
The average duration of the studies was 113 ± 180 (SD)
months, ranging from a minimum of 10 to a maximum of 432
months. All the studies included in the mini review had obtained
ethic committee approval.
Socio-Demographic and Lifestyle Features
Participants’ age ranged from 18 to 98, with a mean of 47.73 ±
3.51 (SD) years. All the included studies involved participants of
both genders. All studies reported sociodemographic data, which
were retrieved from medical records in 6 studies (1, 38, 40–
43); only one study (37) specified details about participants’
occupational status. Six studies provided lifestyle data, obtained
by medical records in 2 studies (38, 41), by the anamnesis in 2
other studies (40, 42), and via a specific questionnaire in the last
2 studies (1, 43)
Seven studies (1, 37, 39–43) analyzed participants’ smoking
habits; this information was retrieved from a direct question in
3 studies (40, 42, 43), from a self-report measure (the Nutrition
and Health Questionnaire) in one study (1), and from previous-
year medical records consultation in another one study (41). The
source of this information was not specified in 2 studies (37, 39).
Alcohol consumption was described by all included studies.
Anyway, only 1 study reported data on participants’ eating
habits (1), as assessed by the Nutrition and Health Information
Questionnaire (32).
Two studies reported information about physical activity: 1
study (48) used the Nurses’ Health Study Activity Questionnaire
(49) and MET-hours per week (a metabolic equivalent is a unit
that describes the energy expenditure of a specific activity) for
each activity (50); 1 study reported data on structured physical
activity or 30min of walking per day (42).
Metabolic Parameters
NCE-ATP III and IDF criteria for MetS were adopted,
respectively, by 5 (39–43) and 3 of the selected studies (1, 37,
38). Seven studies collected blood examinations (1, 37–43); 7
studies recorded blood pressure (1, 37, 39–43); last, 7 studies
reported information about anthropometric measures (1, 37, 39–
43). All the studies included in this mini-review collected data
about hypertriglyceridemia (>150 mg/dl), arterial hypertension
(>130/85 mmHg) and fasting hyperglycemia (>110 mg/dl);
furthermore, 7 studies assessed HDL cholesterol as well (men
<40 mg/dl, women <50 mg/dl) (37–43). Waist circumference
was measured in 6 studies; in 4 of them, abdominal obesity
was diagnosed for values above the following cutoffs: >102 cm
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for men and >88 cm for women (39, 41–43); 2 studies adopted
different cutoff values: >94 cm (1), and >90 cm for men and
>80 cm for women (37), respectively. Seven studies reported data
on BMI (1, 37–43).
Antidepressant Medication and Depressive
Symptoms
Six studies reported data on type of antidepressant agents (37–39,
41–43).
Six studies reported data on SSRI (37–43); only one on
norepinephrine reuptake inhibitors (NRIs) (41); 4 studies on
Serotonin and norepinephrine reuptake inhibitors (SNRI) (37,
39, 41, 42); 3 studies reported data on Tricyclic and tetracyclic
antidepressants (TCA) (38, 39, 42); 3 studies reported data also
on other drugs (37, 39, 41).
With more detail, Stanojevic´ et al. (43) compared 35
SSRI medication-treated patients; Kopf et al. (38) analyzed
78 depressed patients in treatment with amitriptyline or
paroxetine; Salvi et al. (42) involved 294 antidepressant-
treated patients with bipolar disorder, treated with the use
of antidepressants (SSRI, TCA, SNRI, and other medications);
Hung et al. (37) analyzed different antidepressants, including
paroxetine, trazodone, escitalopram, fluoxetine and venlafaxine;
Luppino et al. (39) compared 302 primary care outpatients,
445 secondary care outpatients and 80 inpatients, with major
depressive disorder (MDD), treated with TCA or Serotonin and
norepinephrine reuptake inhibitors (SNRIs) and mirtazapine;
Sagud et al. (41) analyzed patients data in therapy with SSRIs,
SNRIs, tianeptine, mirtazapine, bupropion, reboxetine, and
maprotiline.
Only 1 study reported information about the specific phase
of MDD (41), while 4 studies included details about the severity
of depressive symptoms (38–42). All studies adopted specific
questionnaires for the assessment of depression (1, 38–43). In 7
studies the questionnaire was a clinician-administered interview
(1, 37–39, 41–43), while in 1 study both a clinician-administered
interview and a self-administered questionnaire were used (40).
More specifically, 4 studies (37, 38, 41, 43) used the Hamilton
Depression (HAM-D) Rating Scale (44), one (1) the CES-D
scale (44), one (1) the Zung self-rating depression scale (44),
another one (42) the Clinical Global Impressions Scale (CGI-
BD) (51) and the Structured Clinical Interview (SCID) (52), and
a last one (40) used the Brief Psychiatric Rating Scale (BPRS)
(53), the HAM-D Rating Scale (44), the Spielberger State-Trait
Anxiety Inventory (STAI) (53, 54) and the Personality Diagnostic
Questionnaire (PDQ-4+) (53).
Psychiatric and Medical Comorbidity
Four studies included participants who were treated with other
psychiatric medications beyond antidepressants (37, 38, 40, 43).
One study evaluated cognitive function (1). Five studies analyzed
other psychiatric variables (37, 38, 40–42). Three studies reported
information about medical comorbidities (39, 41), and 2 studies
about treatment for medical conditions beyond depression
(40, 41).
Outcomes and Assessment of the Quality
of Studies
Stroke was reported in 1 study (1), Cardiovascular Disease (CVD)
in 3 studies (37, 39, 41). The NOS scores ranged from 3 to 9, with
a mean score of 5.75± 1.75 (SD).
Cross-Sectional Studies
Sagud et al. (41) assessed 203 inpatients with MDD, including
both treatment resistant (TRD) and non-treatment resistant
(non-TRD) individuals. They did not find any relationship
between MetS and treatment resistance.
Crichton et al. (1) suggested that cardiovascular risk factors
attenuated the relation between depression and MetS; moreover
they shown that, while depression appeared to increase the risk
of CVD (1), CVD could promote the onset of depression.
The cross-sectional study by Salvi et al. (42) involved
294 antidepressant-treated patients with bipolar disorder. No
association was found between the use of antidepressants (SSRI,
TCA, SNRI, and others) and MetS. However, subjects on H1-
R high-affinity antidepressants treatment (N = 15) showed a
higher prevalence of MetS, likely due to the anti-histaminic
effect of this type of antidepressants, which counteracts histamine
central anorexigenic effects (6) and increases adipose tissue
deposition (8).
Luppino et al. (39) compared 302 primary care outpatients,
445 secondary care outpatients and 80 inpatients with MDD.
No significant difference among patients recruited in the three
treatment settings was found either in the prevalence of MetS
(26% primary, 24% secondary care, and 28% inpatients) or in
clinical and laboratory measures including waist circumference
(WC), BMI, LDL cholesterol, glucose and diastolic blood
pressure (DBP). However, inpatients reported higher waist-hip
ratio, total cholesterol and triglyceride levels and lower HDL
cholesterol levels and systolic blood pressure than outpatients.
Results showed significant associations for TCA use with higher
DBP (β = 0.10, P = 0.003) and LDL-cholesterol (β = 0.07,
P = 0.04), while the use of other antidepressants (Serotonin and
norepinephrine reuptake inhibitors-SNRIs and mirtazapine) was
associated with higher triglyceride levels (β= 0.10, P = 0.004).
Hung et al. (37) studied 229 outpatients, 85 males and 144
females, recruited by systematic sampling of 1,147 outpatients
affected by anxiety andmood disorders. The authors analyzed the
impact of pharmacotherapy and psychiatric diagnoses on MetS
and found that 51 (22.3%) subjects of 229 outpatients matched
MetS criteria, likely due to treatment with antipsychotics and
mood stabilizers. The study also shown that antidepressant-
treated (paroxetine, trazodone, duloxetine, escitalopram,
fluoxetine, and venlafaxine) patients and patients treated with
other medication than-antidepressants (antipsychotics and
mood stabilizers) did not significantly differ as far as MetS risk is
concerned.
Margari et al. (40) evaluated the differences in anthropometric
measures, biochemical variables, MetS and cardiovascular risk
in a sample of 83 psychiatric inpatients under pharmacological
treatment and 77 internal medicine patients. Female psychiatric
patients showed higher levels of triglycerides (mg) and of
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homeostatic model assessment (HOMA) index than males.
Patients with unipolar depression reported highest triglycerides
and triglycerides/HDL ratio levels with a strong relation with
antidepressant treatment.
Cohort Studies
Stanojevic´ et al. (43) compared 35 SSRI medication-treated
patients with recurrent depressive disorder and 25 healthy
controls. Elevated C-reactive protein (CRP) levels were found to
be associated with an increased frequency of MetS in depressed
patients. While no statistically significant difference was found
between depressed patients and controls regarding either the
prevalence of MetS or CRP levels, waist circumference and total
cholesterol levels were significantly higher in the first than in the
latter.
Kopf et al. (38) analyzed lipoprotein composition, insulin
sensitivity and salivary cortisol in 78 depressed patients in
treatment with amitriptyline or paroxetine at baseline (t0) and
after 35 days of treatment. No change in quantitative insulin
sensitivity check index (QUICKI) was found after 35 days of
treatment. Moreover, only patients on amitriptyline treatment
showed increased levels of triglycerides (P <0.05). Parameters
of cholesterol metabolism improved slightly without differences
between treatment groups. The authors concluded that both
the antidepressant treatments assessed might exert a mainly
beneficial effect on lipid regulation.
Narrative Analysis
A summary of extracted data is reported in Table 1.
DISCUSSION
Previous studies suggested a higher risk of unhealthy behaviors
(i.e., excessive alcohol consumption, smoking, obesity, lack of
physical activity) (55, 56) in depressed patients, both with
a current depressive episode or with a lifetime diagnosis of
depression (57), which may contribute to their increased risk
of MetS. Moreover, severity of depression seems to correlate
with smoking, obesity and physical inactivity following a dose–
response mechanism (58–60). Actually, Pan and coworkers’
systematic review (18) described an association between
depression and MetS in adults and supported early detection and
management of depression among patients with MetS and vice
versa.
The current mini review included two cohort (37, 41) and
six cross-sectional studies (1, 38–40, 42, 43). Most of them were
performed in Europe and involved a single center. Patients were
recruited from different settings, including psychiatric wards,
outpatient services or both. Six studies reported data on the
type of antidepressant assessed (37–39, 41–43), and 6 studies
included patients treated with other psychiatric medications
beyond antidepressants (37, 38, 40–43).
As regards correlation between MetS and antidepressants use,
only one study (42) showed that the risk of Mets was greater for
patients treated with antidepressants with high affinity binding
to histamine H1-receptors. There seems to be an association
between the use of antidepressant medication and alterations
of lipid profile. In particular, Luppino et al. (39) suggested a
mediating role of TCA and NSRI antidepressant use on the
increase of triglycerides level (40), while Crichton et al. (1)
suggested a correlation with carbohydrate metabolism disorders
(diabetes) and hypertension in patients on antidepressant
therapy. Hung et al. (37) postulated that pharmacotherapy may
lead to over-weight problems.
The studies included in this mini review, consistent with a
previous report on this topic (61), support the hypothesis that,
beyond the use of antidepressant medications, MetS may be
associated with depressive symptoms, especially when associated
with neurovegetative features, and that the inflammatory
response may play a key role in this phenomenon. Indeed, the
study by Stanojevic´ et al. (43) found that elevated CRP levels in
depressed patients were associated with an increased frequency
of MetS.
Two studies included in the mini review (1, 39) support the
idea that the increased rate of Mets in depressed patients might
depend on the involvement of both depressive symptoms and
antidepressants use. In particular, one study (1) showed that,
among patients with depressive symptoms and lower HDL rates,
there seems to be a higher risk of MetS Sagud et al. (41) did not
find any significant difference between TRD and non-TRD in the
occurrence of MetS or cardiovascular risk factors.
Only the cross sectional study by Kopf et al. (38), observed
an inverse correlation between cortisol and cholesterol in
the obese subgroup of amitriptyline or paroxetine-treated
patients, consistent with the widely acknowledged association
of depression and low cholesterol levels (9, 10), and supporting
the hypothesis that antidepressants may exert a mainly beneficial
effect on lipid regulation.
Moreover, studies using IDF criteria reported stronger
correlations among depression and Mets than those using NCEP
ATP-III ones (40–42) with the exception of the study by Kopf
et al. (38).
Strengths
Our mini review followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement
(46). Quality of included studies was assessed with the NOS
(NOS scores ranged from 3 to 9). Accuracy of MEDLINE search
was guaranteed by using MeSH terms and text words related to
research studies on association between MetS, depression and
antidepressants.
LIMITS
The mini review was limited to publications in English language
available in theMEDLINE database. The choice of a simple single
search querymight have caused the inclusion of a limited number
of articles in the mini review. Therefore, it is possible that the
literature search we performed was not comprehensive, and that
excluding other electronic databases and languages other than
English may have caused the exclusion of potentially interesting
articles. Nonetheless, recently it has been suggested that there is
no significant effect on the outcome of a review including only
one database rather than more than one (62, 63).
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CONCLUSIONS
The results of this mini review seem to slightly support the
association among depressive symptoms, antidepressants
therapy and MetS. Nonetheless, due to the absence of
reliable and detailed trial data reported in the studies
included in the review, it could be difficult to tease out
effects of depression from those of the medications
used.
Overall, antidepressants do not seem clearly associated with
MetS, except for H1-R high-affinity ones. Notwithstanding the
limitations described above and the heterogeneity of the selected
studies (i.e., study design, sample size, analysis, participants’
and setting features, classification criteria of depression and
MetS, different antidepressant drugs), implications seem to
emerge especially for antidepressant-treated patients with
depressive symptoms, receiving also antipsychotics or mood
stabilizers, who should be carefully monitored for MetS and the
correlated potentially life-threatening clinical conditions (such as
diabetes/CVD).
Prevention strategies, early diagnosis, integrated and
collaborative health care systems should be available for patients
withMetS and depression; treatment and lifestyle changes should
be considered in high-risk patients.
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